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Abstract:  The intracellular transport of 
exogenous proteins has emerged as one of 
the most promising methodologies for 
biotechnology and chemical biology. 
Current protein delivery is mainly 
approached by liposome encapsulation, 
translational fusion and ionic/hydrophobic 
non-covalent aggregation with transporting 
molecular vehicles. We here introduce the 
concept of supramolecular recognition and 
selective transport of proteins by peptide 
hybrid materials. We have designed a 
helical amphiphilic cationic peptide that 
bears two orthogonal alkoxyamines for the 
precise anchoring of protein ligands. After 
the attachment of these protein ligands, the 
peptide showed a high binding affinity for 
its protein target (i.e. 
mannose/Concanavalin A, 
Biotin/Streptavidin). The resulting 
peptide/protein hybrids were taken up by 
human cells such as HeLa and HepG2. The 
concept described in this manuscript could 
potentially be adapted, through the 
appropriate choice of ligands, to the 
transport of other proteins with suitable 
supramolecular binding motifs. 
Keywords:  Supramolecular 
systems · membranes · peptides · 
penetrating peptides · amphiphiles 
· protein · transport 
 
Introduction 
The selective transport of proteins across the cell membrane is 
a central challenge in protein therapy and chemical biology.[1-4] The 
emergence of protein therapeutics demands innovative methods for 
the intracellular delivery of exogenous antibodies, programmable 
enzymes and transcription factors.[5] Furthermore, expression of 
proteins by standard plasmid transfection or by mRNA protocols 
still suffers from significant limitations related with permanent 
recombination and/or polynucleotides instability.[6] Therefore, as 
biotechnology evolves, we need to develop conceptually new ways 
to transport and deliver proteins inside cells. Classical approaches 
for protein transport include liposome encapsulation, viral delivery, 
covalent capture, electroporation and translational fusion to 
penetrating tags.[2,7] Nature-inspired penetrating peptides[8-13] are 
among the most commonly employed tags in translational fusion.[14-
19] However, protein fusion requires tedious steps of transfection, 
bacterial expression and purification.[2] On the other hand, non-
covalent approaches are mainly based on non-specific electrostatic 
interactions[20] or limited to the biotin/streptavidin couple.[21] New 
techniques have recently been developed to achieve intracellular 
protein delivery.[3,5,22-25] These methodologies include polymeric 
tailoring,[3] dynamic nanoencapsulation,[22] target fusion to 
supercharged proteins[5] and hypertonic induced 
macropinocytosis.[23] However, none of the aforementioned 
examples represents a protocol for selective protein recognition and 
cellular internalization. The design of supramolecular vectors that 
could selectively recognize[26] and transport proteins across the cell 
membrane, without further manipulation, would represent a 
conceptual breakthrough towards the design of selective protein 
delivery vehicles. We envisaged that a hybrid membrane carrier that 
could integrate transport and recognition motifs would be a simple 
approach to tackle this challenge. 
Lectins are carbohydrate-specific proteins that participate in 
numerous biological functions including cellular recognition and 
communication.[27] Reports on peptide folding for improved glycan 
presentation and lectin binding can be found scattered throughout 
the literature.[28-31] Furthermore, lectins are commonly 
overexpressed during tissue inflammation and cellular 
metastasis.[27,32] As a consequence, the delivery of exogenous lectins 
and their conjugates has been explored in the context of cell 
targeting and cancer therapy.[33-35] It has recently been demonstrated 
that peptide structure and helical amphiphilic segregation influence 
critical steps of the delivery process. [10,15,36-41] Helical 
polyglutamates have been developed as antimicrobial agents[42] that 
were subsequently adapted for nucleotide delivery.[43] Balanced 
polymeric glycopeptide hybrids for gene delivery[44,45] and 
nanocapsules for protein and lectin delivery[46,47] have been recently 
developed. However, efforts to equip short penetrating peptides with 
glycan moieties have met with limited success.[48] 
We hypothesized that a short helical peptide would be ideal to 
adjust and orientate cationic, hydrophobic and protein ligand (i.e. 
glycans, biotin) units along a biomimetic scaffold with selective 
protein recognition and membrane translocation properties (Fig. 1A). 
In this peptide, the spatial distribution of charges and 
hydrophobicity would enhance membrane partition and uptake and, 
at the same time, the peptide would perform as a biocompatible 
scaffold for the orthogonal positioning of protein recognition units 
(Fig. 1B). We report here the ‘de novo’ design and synthesis of these 
amphiphilic peptides bearing alkoxyamine connectors for the 
anchoring of protein ligands. After the incorporation of the ligands, 
























































































































































Figure 1. Peptide structure, circular dichroism and proposed model for the selective transport mechanism. A) Minimalist representation of the transporting peptide with amphiphilic 
segregated domains in blue and orange and the protein recognition units in red. Scheme of the different steps involved in selective protein intracellular delivery: recognition, binding, 
transport and release. B) The acronym R1P(R2)(R3) indicates: N-terminal group R1, peptide sequence P and the anchored substituents R2 and R3. Heptad-based wheel diagram for the 
helical conformation of the peptide TmP(Man)2 employed in the cell transport experiments. CD spectra in different conditions: TFE (trifluoroethanol), HKR buffer (pH 7.4) and Egg 
yolk phosphatidylcholine (EYPC) liposomes. The percentage of helicity (at 10ºC) was 26% in neutral-pH buffer, 62% in TFE and 20% in liposome. C) Peptide structure with side 
chains in different colours: cationic (Arg) in blue, hydrophobic (Leu) in orange and modified lysine residues (Lys-R2 and Lys-R3) in red. Substituents in the N-terminal R1: acetyl 
(Ac), TAMRA fluorophore (Tm) and Dexamethasone analogue (Dex). Substituents in the modified lysines R2: Alloc and R2, R3: Acetone, Biotin and α-D-Mannose (Man) O-(2-
acetyl) oximes derivatives. 
 
Concanavalin A and Biotin for Streptavidin). Microscopy images, 
fluorescence quantification, gel electrophoresis, cell viability studies 
and nuclear translocation studies confirmed the uptake of the 
peptide/protein hybrids in two different human cell lines (HeLa and 
HepG2). Overall, these results validated this strategy as a feasible 
methodology for the selectively recognition and transport of proteins 
with a recognisable supramolecular binding motif. 
Results and Discussion 
Design. Recent studies established the influence of guanidinium 
distribution in the delivery properties of penetrating peptides.[37,38,49] 
Polyproline II helical peptides penetrate cells and they only contain 
three aligned guanidiniums.[37,49] Additionally, arginine spatial 
distribution influences the delivery of helical minimal proteins.[38] 
Therefore, we considered the α-helix as an optimal folding motif to 
segregate amphiphilic domains and adjust protein recognition 
ligands in a fully biocompatible peptide scaffold (Fig. 1B). The 
peptide sequence outlined in Fig. 1 follows hydrogen-bonding 
patterns (i+3, i+4) with alternating cationic and hydrophobic 
residues (Fig. 1C). The protein-binding units were located at the 
interface of the hydrophilic/hydrophobic domains to minimize the 
impact on the secondary structure. Peptide synthesis was 
accomplished by a solid phase approach using orthogonal protecting 
groups (Fig. S1).[50,51] The key step was the selective cleavage of the 
methyltrityl (Mtt) groups of the two lysines. Mtt removal proceeded 
in weakly acidic conditions and the reactive alkoxyamines were then 
coupled ‘on resin’ for the subsequent incorporation of aldehydes or 
ketones (R2, R3). The peptide was terminated with either a 
fluorophore (TAMRA), the steroid dexamethasone or by simple 
acetylation (R1, Fig. 1C). Full deprotection and cleavage from the 
solid support was accomplished by TFA treatment and, after 
precipitation and washings, the peptide was re-dissolved in water 
and fused to the protein ligands (R2, R3) by a short incubation with 
the mannosyl aldehyde (5 minutes, quantitative, Fig. S2).[52] After 
HPLC purification the peptide was characterized by circular 
dichroism (CD) in three different solvents: trifluoroethanol (TFE), 
HKR buffer (pH 7.4) and liposomes. The CD of peptide TmP(Man)2 
(where: Tm = TAMRA and Man = α-D-Mannose ligand, Fig. 1B) 
showed the typical bands of the α-helix. This short peptide exhibited 
certain helical behavior in aqueous buffer and in lipid bilayers even 
at high temperatures (60 ºC), although the intensity of the exciton 
couplings diminished (Fig. 1B). 
Binding studies with a model protein Concanavalin A 
(ConA). We initially employed fluorescence anisotropy[53,54] to 
study the binding of the peptide bearing mannose ligands with 
its model protein target (ConA). ConA is a homotetrameric plant 
lectin that presents four saccharide-binding sites that recognises 
with specific affinity α-D-glucose and α-D-mannose residues.[55-57] 
Incubation of the fluorescently-labelled glycopeptides with 
increasing amounts of native ConA resulted in a gradual increase 
of the anisotropy, which indicates the formation of a higher 
molecular weight complex with the protein host (Fig. 2A).[54] 
Initial control experiments with fluorescently labelled methyl α-
D-mannopyranoside and fitting to a 1:1 binding model allowed 
the estimation of a Kd of 137 ± 29 µM, which is consistent 
reported values (Kd ~ 100 µM).[31,53] The peptide TmP(Man)2, 
which contains two orthogonal mannoses, showed the maximum 
net anisotropy value and the best equilibrium dissociation 
constant (Kd = 14 ± 1 µM), which was about one order of 
magnitude higher than that of the mannoside control (Fig. 2A). 
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Figure 2.  Studies of peptide binding with the protein ConA. A) Fluorescence anisotropy titrations and best fitting to a simple 1:1 binding model of fluorescent ligands (Initial 
peptide concentration = 100 nM) with increasing amounts of ConA in HKR buffer (pH 7.4) at 22 ºC. B) Competition experiments on ConA saturated with fluorescently labelled 
mannose followed by the stepwise addition of unlabelled peptides. C) Sensorgrams of the interaction of ConA (9668 µRiU) in the concentration range [Methyl a-D-
mannopyranoside] = 125-1600 µM (orange/black) and [AcP(Man)2] = 7-1000 nM (black/gray). D) Best fitting to a simple 1:1 binding model of the steady-state SPR response for the 
two peptides bearing mannose recognition units. Color code for fitting graphs (A, B, D): black for peptide with two mannoses (TmP(Man)2), red for peptide with one mannose 
(TmP(Alloc)(Man)), grey for peptide capped with two acetones (TmP(Acetone)2) and orange for methyl α-D-mannopyranoside control. In the SPR traces graph, the exact point 
where the ligand flow was stopped is indicated with a blue line. 
 
The role of the mannose for protein binding was confirmed by 
removal of the glycans. Accordingly, the acetone capped peptide 
(TmP(Acetone)2) showed a drop in the binding affinity (Kd = 151 ± 
7 µM). However, the peptide with only one mannose residue, 
TmP(Alloc)(Man), also showed a similar affinity enhancement (Kd 
= 27 ± 4 µM) compared to methyl α-D-mannopyranoside. 
Competition experiments were carried out to gain further insights 
into the stability and specificity of these peptide/protein complexes 
(Fig. 2B). For this purpose, ConA was initially saturated with a 
fluorescently labelled α-D-mannopyranoside. The resulting complex 
was titrated with the competitor that displaced the ligand from its 
binding site (Fig. 2B).[31] As expected, the peptide with the two 
orthogonal mannoses was the best competitor. This peptide was able 
to remove practically all of the labelled mannoside at the lowest 
concentration (IC50 = 98 ± 6 µM). The control peptide with only one 
mannose was less efficient and required more than double the 
concentration to remove only part of the fluorescent 
mannopyranoside (IC50 = 228 ± 21 µM). The peptide capped with 
acetone was not able to displace the mannopyranoside ligand (Fig. 
2B). Surface plasmon resonance (SPR) was employed to further 
confirm this enhancement in binding affinity. The two glycopeptides 
and the methyl α-D-mannopyranoside were flown, at different 
concentrations, over a gold chip biosensor modified by immobilized 
Concanavalin A (Fig. 2C and S3, see methods). The sensorgram for 
the methylmannoside showed an abrupt increase in the resonance at 
time zero and this was followed by an immediate decrease in the 
signal as soon as the analyte stopped flowing (Fig. 2C). The SPR 
profile of the glycopeptide was more complex and when the ligand 
flow was stopped (at t = 240 s), the SPR response decreased 
smoothly and did not recover to the initial level. This profile 
indicated hindered peptide dissociation under pure buffer flow. 
Fitting of the steady state response to a 1:1 equilibrium model 
allowed the estimation of a dissociation constant for the control 
methyl mannoside of 97 ± 12 µM, which is in good agreement with 
recent reports.[58] The SPR Kd constants obtained for the 
glycopeptides (AcP(Man)2 = 0.7 ± 0.1 µM, AcP(Alloc)(Man) = 1.5 
± 0.1 µM) again showed a large increase in the binding affinity (Fig. 
2D). Taken together, the results obtained by the two techniques 
confirmed the importance of the mannose residues for protein 
specific recognition. The binding affinity of the peptide with a 
single mannose ligand, TmP(Alloc)(Man) (Kd = 27 ± 4 µM), was 
higher than that of the methyl α-D-mannopyranoside (Kd = 137 ± 29 
µM). This observation suggested that the peptide is playing a 
synergic and probably unspecific role together with the glycan 
moiety in the stabilization of the final peptide/protein complex. 
Selective recognition and uptake. We next evaluated the 
potential uptake of the protein in HeLa cells (Fig. 3). ConA is 
commonly employed as a cell membrane marker due to its 
aggregation at the cellular membrane glycocalyx (Fig. 3K, 3L).[59] A 
simple cell transport experiment was performed by pre-incubation of 
the protein with different peptides followed by cellular incubation, 
buffer washing and fluorescence microscopy analysis (Fig. 3). An 
initial control experiment was performed with a prototypical 
penetrating peptide such as octaarginine. As expected, CFArg8 (CF 
stands for carboxyfluorescein and Arg8 for octaarginine, see Fig. 
S10) was internalized inside the cells while ConA (labelled with 
Alexa Fluor-647) remained at the cell membrane (Figs. 3D, 3E). 
However, when the transport experiment was repeated with the 
amphiphilic peptide bearing two mannose ligands TmP(Man)2, the 
protein was aggregated with the glycopeptide and cellular uptake 
was observed (Figs. 3I, 3J). Quantification of the peptide and 
protein co-localization gave good values (∼ 0.6) for the Manders 
coefficients (Table S1).[60] 
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Figure 3. Selective recognition and delivery of ConA in cells. The first row (A-E) shows a series of microscopy images of the control peptide CFArg8 (carboxyfluorescein 
conjugate) (4 µM) combined with fluorescent ConA647 (Alexa Fluor-647). The second row (F-G) shows the analogous experiment but with the glycopeptide TmP(Man)2 (3 µM) and 
ConA647. A) and F) Differential interference contrast (DIC) images. B) and G) epifluorescence peptide channel showing that both peptides were internalized. C) and H) 
epifluorescence protein channel: C) ConA remained in the membrane when incubated with octaarginine, H) ConA was internalized when incubated with the glycopeptide 
TmP(Man)2. D) and I) Epifluorescence merge channels. E) and J) CLSM merge channels. CLSM images were stained with Hoechst for nuclear visualization. ConA was ConAFITC 
(fluorescein conjugate). K) and L) Epifluorescence and CLSM (with blue nuclei) of ConAFITC incubated with HeLa cells. M) Epifluorescence image of HeLa cells incubated with 
TmP(Acetone)2 (2 µM) and ConAFITC. N) Epifluorescence image of HeLa cells incubated with TmP(Alloc)(Man) and ConAFITC. O) Epifluorescence images of HeLa cells incubated 
with TmArg6Gly5(Man)2 non-helical control peptide and ConAFITC. Note that in B, C, D, E, H and I the ConA647 and the CFArg8 have been assigned to green and red channels for 
clarity of comparison. In all cases the concentration of fluorescent ConA was 30 nM and it was incubated with the HeLa cells for 30 min at 37 °C in HKR buffer. 
 
As expected, the peptide without mannoses, TmP(Acetone)2, did 
not complex or transport ConA (Fig. 3M). Similarly, the peptide 
bearing a single mannose ligand, TmP(Alloc)(Man), was unable to 
translocate the protein (Fig. 3N). To demonstrate that lectin binding 
and clustering was not sufficient for protein transport, we carried out 
control experiments with two different non-helical peptides with the 
same number of arginines (TmArg6Gly5(Man)2 and TmArg6(Man)2) 
and a short cationic peptide (TmArg2(Man)2), all of them bearing 
two mannose residues (Figs. 3O and S4-S6). The epifluorescence 
images once again confirmed that the ConA could not go beyond the 
cell membrane. Viability studies of the peptide and the 
peptide/lectin complexes were carried out by the colorimetric MTT 
and the propidium iodide exclusion assays (Figs. S7 and S8). Both 
assays confirmed that the peptide alone had low toxicity at the 
concentrations that were employed in protein transport experiments 
(1 to 5 µM). However, viability studies in the presence of peptide at 
a fixed non-toxic concentration (5 µM) and increasing amounts of 
protein (ConA), showed a clear dose-response toxicity effect that 
was much higher than that for the peptide and the protein alone 
(Figs. S7 and S8). This observation constitutes further proof for the 
protein delivery, as ConA receptor-mediated delivery has been 
applied in cytotoxic cancer targeting.[33,35] 
Internalization mechanism. To study the internalization 
mechanism, the uptake was studied in the presence of endocytic 
inhibitors after cell trypsinization to remove membrane bound 
peptides (Fig. 4).[61] Inhibition of energy-dependent pathways at 4 
ºC revealed that around half of the peptide was able to translocate 
the cell membrane (Fig. 4C). In general different inhibitors showed 
a moderate or a medium reduction of the uptake suggesting a 
combination of different endocytic mechanisms operating at the 
same time. The LysotrackerTM assay showed that peptide/protein 
complexes did not co-localize within the lysosomes (Fig. 4B). The 
internalization was also monitored in a fluorescence time-lapse 
video (Video S1, see supporting information). Intriguingly, the 
punctate fluorescence signal observed in the cytosol became 
increasingly diffuse and intense with time (∼ 1 hour, video S1). To 
further study the cytosolic distribution of the peptide alone or in 
combination with the protein, a glucocorticoid-induced GFP-
translocation assay was employed (Fig. 4A, 4D and Fig. S9).[38] In 
this assay cells are transfected with a plasmid to express GFP (green 
fluorescent protein) fused to the ligand-binding domain of the 
glucocorticoid receptor (GR). This receptor is expressed and 
confined at the cytosol and, upon binding to dexamethasone, it 
undergoes a conformational change that triggers its nuclear 
accumulation.[62] Thus, the nuclear distribution of GR-GFP 
(translocation ratio) is an indicator of the earlier cytosolic presence 
of the dexamethasone-labelled peptide (Fig. S9). Incubation of cells 
with DexP(Man)2, both in the absence (red column) and presence of 
ConA (green column), caused a significant increase in the 
translocation ratio, which indicates that the dexamethasone labelled 
peptide is reaching the cytosol (Fig. 4D). 
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Figure 4 | Internalization mechanism and selective protein transport. A) General scheme: I) Discriminatory recognition of ConA in the presence of Streptavidin. II) 
Translocation assay: GR-GFP fused protein is expressed in the pale orange cytoplasm (GFP: green fluorescent protein, GR: glucocorticoid receptor). Cytosolic delivery of the 
peptide incorporating a dexamethasone ligand triggers GR-GFP conformational changes, exposure of NLSs and nuclear translocation of GR-GFP. B) LysotrackerTM assay (see 
methods): peptide is in red, LysotrackerTM is in magenta and protein is in green. C) Endocytic inhibition of the uptake (see supporting information). In the histogram the columns are 
in red for peptide alone, in grey for the peptide/protein complex (following the fluorescence of the labelled peptide TmP(Man)2) and in green (following the fluorescence of labelled 
protein ConAFITC). Cont: control; CPZ: chlorpromazine; MβCD: methyl-β-cyclodextrin; WORT: Wortmannin; CD+CPZ: Combination of MβCD and CPZ; CHLQ: chloroquine; 
HEP: heparin. Error bars indicate SD of three replicates. D) GR-GFP translocation ratios. Translocation ratios columns are in red for the peptide DexP(Man)2 and in green for the 
peptide/protein complex. HKR stands for the control experiment with buffer. DEX stands for the control experiment with neat dexamethasone. Ratios obtained from the analysis of 
40 to 80 cells from 20 to 30 images and calculated with CellProfiler. Error bars indicate SE. The asterisk (*) indicates a significant value with p ≤ 0.05 and (***) p ≤ 0.001 in a two-
tailed t-test with Bonferroni correction. E) Discriminatory recognition and transport of ConA. HeLa cells incubated with a mixture of 30 nM of ConAFITC (green), 30 nM of 
Streptavidin594 (Alexa Fluor-594, red) and with the unlabelled peptide (4 µM) or Lipofectamine 2000. Yellow arrows indicate: membrane-labelling by ConA (mixture of proteins), 
selective internalization of ConA near the nuclei and peptide/protein aggregates (unlabelled peptide) and non-selective aggregates of the two proteins (Lipofectamine 2000) 
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Interestingly, nuclear translocation experiments in the presence 
of clathrin and caveolae inhibitors led to a significant decrease of 
the translocation ratio. This result suggests that the fraction of 
peptide, or its protein complex, that is internalized by clathrin and 
caveolae receptors, is able to escape from these particular endocytic 
pathways. Finally, to confirm the presence of the lectin in the 
cytosol, the ConA was conjugated with the dexamethasone corticoid 
(Fig. 5A, see supporting information). Transport experiments 
confirmed the higher nuclear translocation and thus cytosolic 
presence of the ConA for the peptide vector in comparison with 
control experiments in the absence of peptide or in the presence of 
the Lipofectamine 2000 vector (Fig. 5A). 
Selective transport and scope. In order to demonstrate protein 
discrimination, transport experiments with ConAFITC were carried 
out in the presence of a second labelled protein, namely 
Streptavidin594 (Alexa Fluor-594). As expected, the peptide was 
complexed the ConA and the peptide/protein aggregates did only 
contain the lectin (Fig. 4E). We performed analogous control 
transport experiments with a commercially available nano-vehicle, 
Lipofectamine 2000, which is known to be a suitable excellent 
vehicle for different proteins.[5] These experiments showed that the 
Lipofectamine transported the ConA and the Streptavidin without 
selectivity (Figs. 4E and S12). We could confirm the presence of 
yellow dots of protein aggregates that were composed of 
Streptavidin (red) and ConA (green). 
To confirm the integrity of the cargo, gel electrophoresis was carried 
out for cellular extracts after internalization experiments and 
extensive cell washing and trypsinization (Fig. S13). The gels 
showed no degradation bands confirming the presence of intact 
protein (Fig. S13). The peptide/protein concentration ratio at the 
incubation step had an impact on the complexes size and uptake (Fig. 
S14). AFM measurements were carried out to investigate the sizes 
of peptide protein clusters (Fig. S15). The AFM micrographs 
confirmed the presence of aggregates of different sizes. However, 
due to the high polydispersity of these aggregates, the correlation of 
their sizes with the uptake efficiency was proven challenging (Fig. 
S15). 
We next exchanged the glycan unit for a biotin ligand to explore the 
extension of the methodology to different proteins (Fig. 1C, Fig. 
S11). Incubation of the biotinylated peptide (AcP(Biot)2) with 
fluorescently labelled Streptavidin and subsequent cell transport 
experiments confirmed the presence of internalized Streptavidin as 
shown in the fluorescence confocal micrographs (Fig. 5B). Finally, 
protein transport experiments in HepG2 cells were performed to 
explore the extension of the method to different cell lines. These 
transport experiments, in a different cell line, showed similar results 
as the previously observed with HeLa cells. In this case, the protein 
targets (ConA and Streptavidin) were incubated with HepG2 cells in 
the presence (or absence) of the acetylated peptides bearing the 
corresponding mannose and biotin ligands. The micrographs of the 
cells confirmed the presence of internalized fluorescent proteins 
when the peptide vehicle was present (Fig. 5C and 5D). On the other 
hand, in the absence of peptides, the pictures showed the membrane 





The objective of this study was to introduce the supramolecular 
recognition and the selective uptake of proteins. For this purpose we 
have designed an amphiphilic peptide that displayed orthogonal 
dynamic connectors[8] for protein ligand anchoring. Two assays 
(SPR and fluorescence anisotropy) confirmed the increased affinity 
of the peptide bearing two mannoses for its host protein  (Con A). 
The enhanced affinity observed for the peptide with a single glycan 
unit compared with the methylmannoside suggested a potential 
unspecific synergic interaction between the peptide and the protein. 
Electrostatic interactions between the cationic peptide and ConA, a 
protein with a net negative charge,[63] could be involved in the 
stabilization of the peptide/protein complex. The good fitting of the 
anisotropy data and the plateau observed for the surface plasmon 
resonance response, supported a fitting to 1:1 binding model. 
Furthermore, the experimental observation that the Kd value 
obtained for the peptide with two mannoses was approximately half 
the value for the peptide with one mannose (TmP(Man)2: Kd = 14 ± 
1 µM vs TmP(Alloc)(Man): Kd = 27 ± 4 µM) suggested that there 
was no cooperativity involved. Peptide helicity did not dramatically 
increase the binding affinity with the protein (Table S2). However, 
the helicity did increase the structural order of the peptide/protein 
complex as observed by fluorescence anisotropy. Substitution at the 
N-terminal with either a fluorophore or an acetyl group did not have 
strong influence in the binding and/or in the cell internalization 
(Figs. 2, 3 and 4E). Different endocytic inhibitors showed a slight (∼ 
20%) decrease in total uptake, suggesting that different 
internalization mechanisms could be operating at the same time.[64] 
The nuclear translocation assay confirmed that the peptide and the 
protein were able to reach the cell cytosol. The results reported here 
constitute a proof of concept for protein selective recognition and 
delivery. However, performing these experiments in complex 
biological media can be challenging as for instance, the presence of 
glucose and serum proteins can block recognition and hinder uptake. 
Although, we could perform the protein selective uptake 
experiments in two cell lines (HeLa and HepG2), the different 
glycosylation pattern and metabolic rate of other different cells 
might have a strong influence on the endocytic uptake of these and 
other lectins. However, the presence of a penetrating peptide 
counterpart that could assist in the endosomal escape will certainly 
enhance the presence of the cytosolic levels of the proteins 
transported.  
Conclusions 
In this work we have introduced the concept of supramolecular 
recognition and uptake of proteins across the cell membrane by 
biomimetic peptide materials. We have applied this concept to the 
selective uptake of ConA and Streptavidin in two different cell lines 
such as HeLa and HepG2 cells. Microscopy images, fluorometry 
quantification, cell viability and nuclear translocation experiments 
confirmed the selective recognition and delivery of two protein 
targets in two different cell lines. We believe that this strategy could 
be adapted, through an informed choice of ligands, to other proteins 
with a recognisable supramolecular binding motif. In this regard, the 
peptide scaffold described here will allow the conjugation of 
different ligands and reducing glycans through its nucleophilic 
linkers. These hybrid biomaterials and this methodology could find 




























B) i) Streptavidin488 ii) Streptavidin488 + AcP(Biot)2 iii) Streptavidin488 + AcP(Biot)2
C) D)
ConAFITC ConAFITC+ AcP(Man)2 Streptavidin594 Streptavidin594 + AcP(Biot)2
 
Figure 5 | Cytosolic presence and extension to Streptavidin. A) Cytosolic presence of ConA. Schemes for activation of dexamethasone, ConA labelling and transport experiment 
are shown on the left. Nuclear translocation ratio for dexamethasone labelled ConA: buffer (HKR), dexamethasone (Dex), dexamethasone labelled protein (ConA-Dex), acetylated 
di-mannosyl peptide combined with ConA-Dex (AcP(Man)2) and Lipofectamine 2000 combined with ConA-Dex (Lipo). B) CLSM images of HeLa cells incubated with 
Streptavidin488 in the absence i) or presence ii) and iii) of the peptide AcP(Biot)2. The concentration of [Streptavidin488] was 5 µM in i), 3 µM in ii) and 5 µM in iii). The peptide 
[AcP(Biot)2] concentration was 4 µM. C) ConA transport in HepG2 cells. HepG2 cells were incubated with 30 nM ConAFITC (green) in the presence or not of 3 µM of AcP(Man)2. 
D) Streptavidin transport in HepG2 cells. HepG2 cells were incubated with 3 µM Streptavidin594 in the presence or absence of 4 µM AcP(Biot)2. 
Methods 
Full experimental details for peptide synthesis, circular dichroism, 
fluorescence assays, surface plasmon resonance, cellular uptake, inhibition 
experiments and nuclear translocation assays can be found in the supporting 
information. 
Peptide synthesis. All peptides were synthesized by manual Fmoc solid-
phase peptide synthesis using Rink Amide resin. Full details of the synthesis 
can be found in the supporting info. The characterization was performed by 
analytical HPLC, 1H NMR spectroscopy, and low and high-resolution mass 
spectrometry. 
 
Fluorescence anisotropy. Fluorescence anisotropy measurements were 
carried out at 20 °C in a quartz cell of 1 cm path length at a final volume of 
0.6 mL using the following settings: integration time: 1.0 s; excitation slit 
width: 3.0 nm; emission slit width: 3.0 nm; excitation wavelength 559 nm; 
emission wavelength 585 nm. ConA was dissolved in 0.1 M HEPES buffer, 
pH 7.4, containing 0.9 M NaCl, 1 mM MnCl2 and 1 mM CaCl2, which were 
added to the solution containing 100 nM ligand (Tm-peptides) in 0.1 M 
HEPES buffer, pH 7.4, containing 1 mM MnCl2, 1 mM CaCl2, 0.9 M NaCl 
and varying the lectin (ConA) concentration from 1 to 300 µM. Competition 
titration experiments were performed using 150 µM Concanavalin A in 0.1 
M HEPES buffer (pH 7.4) containing 1 mM MnCl2, 1 mM CaCl2, 0.9 M 
NaCl, 160 nM 4-methylumbelliferyl α-D-mannopyranoside (excitation 
wavelength 355 nm; emission wavelength 460 nm) and varying the 
unlabelled peptides concentration from 10 to 300 µM. The data was fitted to 
a 1:1 equilibrium model to evaluate the Kd. 
 
Surface plasmon resonance. ConA was immobilized in one vertical channel 
of a GLH chip in HEPES buffer (10 mM HEPES, 150 mM NaCl, 1 mM 
CaCl2, 1 mM MgCl2 and 0.005% Tween 20, pH 7.4) at 25 ºC. Two channels 
of the chip were activated for 300 s, at a flow rate 30 µL/min, using a 
mixture of 40 mM EDC and 10 mM sulfo-NHS. This was followed by an 
injection of 300 µL of ConA, at 30 µg/mL, in 10 mM acetate buffer (pH 4.0) 
in the first channel, and in the second channel 10 mM acetate buffer was 
used as reference. Finally, 1 M ethanolamine-HCl (pH 8.5) was injected, at a 
flow rate of 30 µL/min, for 300 s to deactivate any remaining activated 
 8 
carboxyl groups. This resulted in the immobilization of 9668 RU of ConA. 
The chip was then rotated by 90o and buffer injections were performed until 
a stable signal was achieved (for at least 30 min). The Methyl α-D-
mannopyranoside was applied at a flow rate of 50 µL/min for 120 s in the 
association phase, which was followed by a 180 s dissociation phase. The 
two peptides were applied at a flow rate of 50 µL/min for 240 s in the 
association phase, which was followed by a 180 s dissociation phase. The 
steady state response was fitted to a 1:1 equilibrium model to evaluate the Kd. 
 
Cell transport experiments. HeLa cells growing on four chamber glass 
bottom dishes were washed with HEPES–Krebs–Ringer (HKR) buffer (5 
mM HEPES, 137 mM NaCl, 2.68 mM KCl, 2.05 mM MgCl2, 1.8 mM CaCl2, 
pH 7.4) and nuclei were stained by incubation with 1 µM Hoechst 33342 in 
HKR for 30 min. The peptide and protein were diluted in HKR and 
incubated for 7 min at room temperature to allow the formation of the 
complexes. Cells were washed with HKR and incubated with the complexes 
for another 30 min. Cells were washed again to remove excess peptide 
before performing epifluorescence microscopy using a Nikon Eclipse Ti-E 
inverted microscope or confocal microscopy with a Leica SP5 microscope. 
For lysosomal staining, cells were further incubated for 15 min with 100 nM 
Lysotracker Green DND-26 before imaging. Images were analyzed with 
ImageJ and the co-localization parameters (Manders coefficients) were 
calculated using the Coloc2 plugin selecting the Costes method of threshold 
regression (Table S1). 
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